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MaBACKGROUND MicroRNA (miR) dysregulation in the myocardium has been implicated in cardiac remodeling after injury
or stress.
OBJECTIVES The aim of this study was to explore the role of miR in human CD34þ cell (hCD34þ) dysfunction in vivo
after transplantation into the myocardium under ischemia-reperfusion (I-R) conditions.
METHODS In response to inﬂammatory stimuli, the miR array proﬁle of endothelial progenitor cells was analyzed using
a polymerase chain reaction–based miR microarray. miR-377 expression was assessed in myocardial tissue from human
patients with heart failure (HF). We investigated the effect of miR-377 inhibition on an hCD34þ cell angiogenic proteome
proﬁle in vitro and on cardiac repair and function after I-R injury in immunodeﬁcient mice.
RESULTS The miR array data from endothelial progenitor cells in response to inﬂammatory stimuli indicated changes in
numerous miR, with a robust decrease in the levels of miR-377. Human cardiac biopsies from patients with HF showed
signiﬁcant increases in miR-377 expression compared with nonfailing control hearts. The proteome proﬁle of hCD34þ
cells transfected with miR-377 mimics showed signiﬁcant decrease in the levels of proangiogenic proteins versus
nonspeciﬁc control–transfected cells. We also validated that serine/threonine kinase 35 is a target of miR-377 using a dual
luciferase reporter assay. In a mouse model of myocardial I-R, intramyocardial transplantation of miR-377 silenced
hCD34þ cells in immunodeﬁcient mice, promoting neovascularization (at 28 days, post–I-R) and lower interstitial ﬁbrosis,
leading to improved left ventricular function.
CONCLUSIONS These ﬁndings indicate that HF increased miR-377 expression in the myocardium, which is detrimental
to stem cell function, and transplantation of miR-377 knockdown hCD34þ cells into ischemic myocardium promoted their
angiogenic ability, attenuating left ventricular remodeling and cardiac ﬁbrosis. (J Am Coll Cardiol 2015;66:2214–26)
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AB BR E V I A T I O N S
AND ACRONYM S
EPC = endothelial progenitor
cell
HF = heart failure
HUVEC = human umbilical vein
endothelial cell
IHD = ischemic heart disease
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2215H eart failure (HF) has been classiﬁed as anepidemic of the 21st century and is nowthe major cause of morbidity in the United
States (1). A number of cardiac pathophysiological
conditions, including myocardial infarction (MI) and
ischemia reperfusion (I-R) injury that leads to HF,
are associated with activation of inﬂammatory medi-
ators in the heart (2).SEE PAGE 2227 I-R = ischemia-reperfusion
LPS = lipopolysaccharide
LV = left ventricular
MI = myocardial infarction
miR = microRNA
mRNA = messenger RNA
qRT-PCR = quantitative
reverse transcriptase
polymerase chain reaction
STK35 = serine/threonine
kinase 35
UTR = untranslated region
VEGF = vascular endothelial
growth factorDespite our belief that the heart has limited
regenerative capacity, murine endothelial progenitor
cells (EPCs) and human CD34þ (hCD34þ) cell–based
therapy provide substantial clinical beneﬁts for
ischemic diseases, such as chronic angina, MI, and
HF (3,4). These cells, through paracrine-mediated
growth factor secretion, induce neoangiogenesis/
vasculogenesis and therefore augment cardiac cell
survival and function (5). The major tissue factors for
poor clinical outcome include hostile ischemia and
chronic inﬂammatory tissue microenvironments into
which the cells are introduced.
Recently, microRNAs (miR; approximately 20 to 22
nucleotides long) have elicited substantial interest as
regulators of and therapeutic targets for HF (6). miR
dysregulation after cardiac injury has been implicated
in several biological processes involved in cardio-
vascular diseases (7,8). However, studies to under-
stand the deleterious effect of miR dysregulation on
hCD34þ cells or murine EPCs in response to an in-
ﬂammatory stimulus and its implications on cardiac
regeneration and repair after myocardial trans-
plantation have been limited.
So far, the role of miR-377 in hCD34þ cell or EPC
biology and function has never been explored.
Moreover, it is unknown whether altering miR-377
expression affects hCD34þ cell–induced angiogenesis
in ischemic myocardial tissue. Therefore, deter-
mining the role of miR-377 in hCD34þ cell or EPC
biology and function and its molecular mechanisms
could be of major signiﬁcance for stem cell–based
therapy aimed at regeneration of heart tissue.
In this study, we ﬁrst sought to determine the al-
terations of miR in mouse EPCs under inﬂammatory
conditions and cardiac biopsies from patients with
HF. We further tested whether knockdown of miR-377
in hCD34þ cells could affect the angiogenic response
in ischemic myocardium.
METHODS
EPCs isolated from the bone marrow of C57BL/6J male
mice (Jackson Laboratories, Bar Harbor, Maine) were
cultured as described previously (9). Detailedmethodology is provided in the Online
Appendix. EPCs were subjected to lipopoly-
saccharide (LPS) treatment (25 ng/ml) for 12 h
(to stimulate inﬂammatory response). Un-
treated cells served as controls. miR expres-
sion was analyzed using a polymerase chain
reaction (PCR)–based miR microarray plat-
form covering a total of 352 mouse miR. Data
analysis was performed using Internet-based
software for miR PCR array systems.
Heart tissue samples were obtained from
failing human hearts at the time of trans-
plantation at the Houston Methodist DeBakey
Heart & Vascular Center, Houston Methodist
Hospital (Houston, Texas), immediately
frozen in liquid nitrogen, and stored at 80C
until use. Normal tissue samples were ob-
tained from donor hearts not used for trans-
plantation and were collected and stored in
the same manner. All tissues were collected
under an approved protocol by the Houston
Methodist Research Institutional Review
Board.ISOLATION OF CELLS AND STUDY DESIGN.
Cardiomyocytes were isolated from 12-week-old
C57BL/6J male mice after 3 days of myocardial I-R by
Langendorff perfusion and the Thompson proce-
dure (10). For isolation of adult cardiac endothelial
cells, CD31þ cells were isolated via magnetic-activated
cell sorting separation using anti-biotin CD31 micro-
beads (Miltenyi Biotec, San Diego, California), and
CD31 cells were depleted. Purity of CD31þ cells was
conﬁrmed by immunohistochemistry for CD31 on
cytospins of freshly isolated CD31þ/CD31 cardiac cells.
To determine the role of miR-377 in hCD34þ cells,
the condition medium collected from culturing
hCD34þ cells transfected for 48 h with miR-377 mimic
(60 nm/l), inhibitor (60 nm/l: anti–miR-377), miR
mimic, or miR inhibitor negative control was analyzed
using Proteome Proﬁler (human angiogenesis anti-
body array, R&DSystems,Minneapolis,Minnesota) per
the manufacturer’s instructions. Data were analyzed
via ImageQuant LAS 4000 software (GE Healthcare,
Waukesha, Wisconsin). The detailed transfection
method is provided in the Online Appendix.
Human umbilical vein endothelial cells (HUVECs)
were cotransfected with miR-377 mimic (60 nm/l),
miR-377 inhibitor (60 nm/l), or miR mimic or inhibitor
negative control (60 nm/l) and a reporter plasmid con-
taining the 30-untranslated region (30-UTR) of serine/
threonine kinase 35 (STK35; HmiT003085-MT06,
100 ng), mutated 30-UTR of STK35 (CS-HmiT003085b-
MT06-01, 100 ng), or corresponding control empty
FIGURE 1 miR Array Analysis of EPCs in Response to Inﬂammatory Stimuli
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(A) Heat map shows microRNA (miR) expression in control and lipopolysaccharide (LPS)-treated endothelial progenitor cells. (B) Location of the miR in the heat map and
their relative expression. (C) Validation of miR-377 expression in control and LPS-treated human CD34þ cells by quantitative reverse transcriptase polymerase chain
reaction (normalized to control U6; n ¼ 3). *p < 0.05. EPC ¼ endothelial progenitor cell.
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2216luciferase reporter vector (CmiT000001-MT06, 100 ng,
GeneCopoeia, Rockville, Maryland). The miR and re-
porter plasmid were mixed with Lipofectamine 2000
(Thermo Fisher Scientiﬁc, Tewksbury, Massachusetts)
and added to a 48-well plate containing HUVECs
(1.3 104). After a 24-h transfection, luciferase activity
was assessed using a dual luciferase reporter assay kit
(Promega, Madison, Wisconsin) per manufacturer’s
protocol.
Twelve-week-old severe combined immunodeﬁ-
ciency (SCID) mice were subjected to myocardial
ischemia for 30 min by temporary ligation of the left
anterior descending coronary artery followed by
reperfusion for 28 days as described previously
(11,12). Immediately after ischemia was completed
and reperfusion begun, mice received intramyo-
cardial injection of hCD34þ cells (5  104) transfected
with either miR-377 inhibitor or miR inhibitor nega-
tive control at 3 different sites in the ischemia
area. The hCD34þ cells were labeled using a PKH26
red ﬂuorescent cell linker kit (Sigma-Aldrich, St.Louis, Missouri) per manufacturer’s protocol. Trans-
planted hCD34þ cells were detected at 24 h after in-
jection by immunoﬂuorescence, and left ventricular
(LV) functional changes and structural remodeling
were evaluated 28 days after I-R.
STATISTICAL ANALYSIS. Data are presented as
mean  SE. An unpaired Student t test was performed
between 2 groups of mice to determine statistical sig-
niﬁcance. When more than 2 groups were involved,
analysis of variance with a Tukey post-hoc test
was used to analyze the data. Probability (p) values
of <0.05 were considered statistically signiﬁcant.
RESULTS
Our previous study showed that prolonged inﬂam-
matory response in the myocardium is detrimental
for EPC function (9). To determine the miR proﬁle of
EPCs under myocardial inﬂammatory conditions, we
treated bone marrow–derived EPCs (mouse) with LPS
(25 ng/ml) for 12 h and performed a quantitative
FIGURE 2 miR-377 Expression in Failing Human Hearts
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As measured by quantitative reverse transcriptase polymerase
chain reaction, microRNA 377 (miR-377) expression was signiﬁ-
cantly upregulated in failing versus nonfailing human heart
samples (normalized to control group U6; n ¼ 5). *p < 0.05.
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2217reverse transcriptase PCR (qRT-PCR)–based miR array
analysis. The miR array data analysis showed that
several miR were differentially expressed with
robust decreases in miR-377 expression in EPCs
treated with LPS (Figures 1A and 1B [well 7C]). We
further validated miR-377 expression in LPS-treated
hCD34þ cells (Figure 1C) using qRT-PCR. The results
consistently showed signiﬁcant decreases in miR-377
expression upon LPS treatment (p < 0.05 vs. control
untreated cells). Further, we conﬁrmed similar re-
sults in the mouse EPCs (Online Figure 1A) and
HUVECs (Online Figure 1B) upon LPS treatment
versus control (p < 0.05). The miR array data (heat
map and expression) of all of the miR analyzed are
depicted in Online Figure 2.
miR-377 EXPRESSION IN HUMAN FAILING HEARTS. To
determine the effect of HF on miR-377 expression,
cardiac biopsies were collected from the LV free wall
of patients with ischemia at the Houston Methodist
DeBakey Heart & Vascular Center. The qRT-PCR re-
sults showed that the miR-377 expression was
signiﬁcantly upregulated in human heart tissue
samples from patients with HF compared with pa-
tients with non–cardiac-related ailments (p < 0.05)
(Figure 2).
To determine ischemia-induced miR-377 expres-
sion in different cardiac cell types, we isolated car-
diomyocytes, endothelial cells (CD31þ), and CD31
cells from mouse hearts with sham or I-R procedure,
3 days post-surgery, and assessed miR-377 expressionby qRT-PCR analysis. I-R injury increased miR-377
expression in all of the cardiac cell types versus
levels in sham-operated mice (p < 0.05) (Figure 3).
These data, together with the miR-377 expression in
the human failing hearts, prompted us to evaluate the
effect of increased miR-377 expression in the
myocardium on hCD34þ cells that will be introduced
into the myocardium for cell-based therapy.
Previous reports have suggested that the beneﬁcial
effect of hCD34þ cell therapy is mediated through
paracrine secretion of growth factors that aid in
angiogenic response (13). To determine the effect of
miR-377 on paracrine secretion of angiogenic factors
in hCD34þ cells, a proteome proﬁle of condition
medium of hCD34þ cells transfected with miR-377
mimic, miR-377 inhibitor, or respective negative
controls was performed using a human angiogenesis
array. Figure 4 shows that miR-377 mimic treatment
signiﬁcantly decreased secretion of various pro-
angiogenic factors, such as vascular endothelial
growth factor (VEGF), matrix metalloproteinase 9,
platelet-derived growth factor AA, hepatocyte
growth factor, insulin-like growth factor–binding
protein 1, endocrine gland–derived VEGF, endothe-
lin 1, angiopoietin 1, and angiopoietin 2 compared
with the conditioned media of the miR mimic nega-
tive control–transfected hCD34þ cells (p < 0.05)
(Figure 4). Some of the antiangiogenic proteins, like
serpin E1, serpin F1, thrombospondin 1, urinary plas-
minogen activator, platelet factor 4, angiogenin,
angiostatin, and artemin, were expressed at signiﬁ-
cantly higher levels in the conditioned media
collected from miR-377 mimic–treated hCD34þ cells
compared with miR mimic negative control–trans-
fected hCD34þ cell–conditioned media. On the con-
trary, miR-377 inhibitor treatment showed higher
proangiogenic factor and lower antiangiogenic factor
secretion compared with miR-377 mimic–treated cell-
conditioned media (p < 0.05) (Figure 4).
Vasculogenesis is a dynamic process involving
migration, differentiation, endothelial cell engraft-
ment, and vascular tube formation (14). To ﬁrst
determine the effect of miR-377 on migratory
response of endothelial cells, we transfected HUVECs
with miR-377 mimic, miR-377 inhibitor, or respective
negative controls and assessed their migration to-
ward a well-known stimulant VEGF using a modiﬁed
Boyden chamber migration assay as described earlier
(11). HUVECs transfected with miR-377 mimic
demonstrated signiﬁcantly lower levels of migration
in response to VEGF stimulation compared with
control nonspeciﬁc transfection (p < 0.05), whereas
HUVECs transfected with miR-377 inhibitor showed
signiﬁcantly higher levels of migration in response to
FIGURE 3 Upregulated miR-377 Expression in Ischemic Mouse Hearts
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In (A) cardiomyocytes and (B) CD31þ cells and (C) CD31 cells isolated from mouse hearts subjected to ischemia-reperfusion (I-R) or sham
operation, I-R signiﬁcantly upregulated microRNA 377 (miR-377) expression (normalized to control U6; n ¼ 6). *p < 0.05.
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2218VEGF stimulation compared with miR inhibitor
negative control (p < 0.05) (Figure 5A).
Furthermore, we analyzed the effect of miR-377
on morphogenesis of HUVECs into vascular tubes.
HUVECs transfected with miR-377 mimic showed
signiﬁcantly reduced ability and those transfected
with miR-377 inhibitor displayed signiﬁcantly in-
creased ability to form vascular tubes compared withtheir respective negative controls (each p < 0.05)
(Figure 5B).
STK35 3 0-UTR: DIRECT TARGET OF miR-377. miR
bind to the 30-UTR of target messenger RNA
(mRNA) and regulate gene expression via post-
transcriptional, translational repression or mRNA
destabilization. To identify potential target genes
involved in miR-377–mediated regulation, speciﬁcally
FIGURE 4 Proteome Proﬁle of Conditioned Media From hCD34þ Cells
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2219those involved in angiogenic processes, we per-
formed computational miR target prediction analysis
using the miR databases and target prediction tools,
TargetScan, miRBase, and PicTar. STK35, also known
as CLP36-interacting kinase 1 or STK35 long form, is
listed as one of the top potential targets for miR-377
and contains complementary seed sequence in its
30-UTR that is highly conserved among human,
chimpanzee, mouse, rat, guinea pig, rabbit, dog, cow,
elephant, and horse RNA (Figure 6A). Unlike other
cytoplasmic kinases, STK35 is a novel kinase,
mainly localized to the nucleus and nucleolus,
that binds to nuclear actin (15); thus, it might play a
critical role in directly modulating gene transcription
machinery (16). A previous study showed thatVEGF stimulation in endothelial cells upregulated
STK35 expression and that STK35 knockdown led to
diminished angiogenic ability of endothelial cells (15).
We ﬁrst examined the impact of miR-377 mimic
and miR-377 inhibitor on STK35 mRNA and protein
expression in HUVECs. The effect of miR-377 mimic or
inhibitor transfection on miR-377 expression was
conﬁrmed by qRT-PCR in HUVECs and hCD34þ cells
(Online Figures 3A and 3B). The effect of miR-377
on STK35 expression was validated by both qRT-PCR
and Western blot methods. Levels of STK35 mRNA
and protein expression were decreased by miR-377
mimic and increased by miR-377 inhibitor compared
with their respective negative controls (p < 0.05)
(Figures 6B and 6C).
FIGURE 5 miR-377 Mimic Inhibits HUVEC Migration and Vascular Tube Formation
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2220Next, to validate whether STK35 30-UTR is a direct
target of miR-377, HUVECs were transfected with
a dual luciferase reporter vector containing the
30-UTR of STK35 or mutated 30-UTR of STK35 along
with miR-377 mimic, miR-377 inhibitor, or its
respective negative controls. miR-377 inhibitorsigniﬁcantly increased luciferase activity versus
miR inhibitor negative control–treated cells, whereas
cells transfected with miR-377 mimic showed
approximately 40% decrease in luciferase activity
compared with miR mimic negative control–treated
cells (both p < 0.05) (Figure 6D). No change was
FIGURE 6 Validation of STK35 as miR-377 Target
A
C
STK35
β–Actin
STK35
β–Actin
B
D
1.2
1
0.8
0.6
0.4
0.2
0S
TK
35
 / 
GA
PD
H 
m
RN
A 
Ex
pr
es
sio
n
(F
ol
d 
Ch
an
ge
 v
s C
on
tr
ol
)
MiR Mimic
Negative Control
MiR–377 Mimic
*
3.5
3
2.5
2
1.5
1
0.5
0S
TK
35
 / 
GA
PD
H 
m
RN
A 
Ex
pr
es
sio
n
(F
ol
d 
Ch
an
ge
 v
s C
on
tr
ol
)
Anti–miR
Negative Control
Anti–miR–377
#
1.2
1
0.8
0.6
0.4
0.2
0
Re
la
tiv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
MiR Mimic
Negative Control
MiR–377 Mimic MiR–377 Mimic
*
STK35–3’UTR
Mutated
STK35–3’UTR STK35–3’UTR
Mutated
STK35–3’UTR
Anti–miR
Negative Control
Anti–miR–377 Anti–miR–377
4
3.5
3
2.5
2
1.5
1
0.5
0
Re
la
tiv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
#
Conserved
predicted consequential pairing of
target region (top) and miRNA (bottom)
Position 4619–4625 of STK35 3’ UTR
Position 4756–4763 of STK35 3’ UTR
5 ’ . . .UAAUCUAGGACCUACGUGUGAAC. . .
3 ’ UGUUUUCAACGGAAACACACUA
5 ’ . . .AAAUUAAGGGACGUUUGUGUGAA. . .
3 ’ UGUUUUCAACGGAAACACACUA
hsa–miR–377
hsa–miR–377
(A) Computational miR target prediction analysis shows that STK35 has complementary sequences for miR-377 that are highly conserved
(white fonts) in most mammals. STK35 messenger RNA (B) and protein expression (C) were measured in the HUVECs transfected with miR-377
mimic or inhibitor or respective controls by quantitative reverse transcriptase polymerase chain reaction and Western blot. (D) Quantitative
data for dual luciferase reporter assay (n¼ 3). *p < 0.05 (miR-377 mimic vs. miR mimic negative control). #p < 0.05 (miR-377 inhibitor vs. miR
inhibitor negative control). GAPDH¼ glyceraldehyde-3-phosphate dehydrogenase; STK35¼ serine/threonine kinase 35; 30UTR¼ 30-untranslated
region; other abbreviations as in Figures 4 and 5.
J A C C V O L . 6 6 , N O . 2 0 , 2 0 1 5 Joladarashi et al.
N O V E M B E R 1 7 / 2 4 , 2 0 1 5 : 2 2 1 4 – 2 6 MicroRNA-377 Knockdown Human CD34+ Cells Enhance Cardiac Function
2221observed in mutated STK35–treated cells with both
miR-377 mimic/inhibitor compared with their
respective negative control transfections. These data
indicated that STK35 is a direct target of miR-377.
Our in vitro data revealed that miR-377 has
a negative inﬂuence on hCD34þ cell secretion of
proangiogenic paracrine factors coupled with reducedendothelial migration and morphogenesis. To assess
the effect of miR-377 inhibition on hCD34þ cell–
mediated cardiac repair, we evaluated capillary den-
sity and ﬁbrosis in the myocardium and LV function
on day 28 after myocardial I-R injury followed by
PKH26-labeled hCD34þ cell transplantation (Online
Figure 4 showing transplanted cells in the
FIGURE 7 Myocardium Capillary Density
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Representative immunoﬂuorescence images taken within the infarct border zone of mice receiving (A) sham treatment or human CD34þ
(hCD34þ) cells treated with (B) anti-microRNA (miR) negative control or (C) anti–miR-377. (D) Graph depicting capillary density across
treatments presented as the number of CD31þ cells (n ¼ 4). *p < 0.05 (hCD34þ cells treated with anti-miR negative control or anti–miR-377 vs.
sham-operated group). #p < 0.05 (hCD34þ cells treated with anti–miR-377 vs. hCD34þ cells treated with anti-miR negative control group).
Joladarashi et al. J A C C V O L . 6 6 , N O . 2 0 , 2 0 1 5
MicroRNA-377 Knockdown Human CD34+ Cells Enhance Cardiac Function N O V E M B E R 1 7 / 2 4 , 2 0 1 5 : 2 2 1 4 – 2 6
2222myocardium). Themice receiving hCD34þ cells treated
with anti–miR-377 negative control showed a trend
toward increased capillary density versus sham-
operated mice (p < 0.05) (Figures 7A, 7B, and 7D); mice
receiving anti–miR-377–treated hCD34þ cells had a
further increase in the number of capillaries compared
with mice receiving hCD34þ cells treated with
anti-miR negative control (p < 0.05) (Figures 7B to 7D).
Furthermore, we assessed the relevance of anti–
miR-377–transfected hCD34þ cells on LV remodeling
and functional recovery. Although not statistically
signiﬁcant, infarct size after 28 days post–I-R was
reduced in mice receiving anti–miR-377 hCD34þ cells
(Figures 8A to 8D). Mice receiving anti–miR-377–
treated hCD34þ cells showed signiﬁcantly lower
interstitial ﬁbrosis in the myocardium compared with
controls (p < 0.05) (Figures 8E to 8H).LV function analysis using echocardiography at 28
days post–I-R showed decreased LV function versus
sham-operated mice (p < 0.05) (Figures 8I and 8J).
Mice receiving anti–miR-377–treated hCD34þ cells
demonstrated signiﬁcant improvement in LV func-
tion, with increased percent ejection fraction and
fractional shortening compared with mice receiving
negative control–treated cells (p < 0.05) (Figures 8I
and 8J). These data suggest that miR-377 inhibition
in hCD34þ cells promotes their angiogenic ability in
the myocardium and attenuates myocardial I-R–
induced ﬁbrosis and LV dysfunction.
DISCUSSION
Current medical therapies have improved the prog-
nosis of patientswithMI. Despite these advancements,
FIGURE 8 Cardiac Fibrosis and Left Ventricular Functional Recovery After I-R
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Abbreviations as in Figures 3 and 4.
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2223signiﬁcant mortality and increased risk for reoccur-
rence of HF remain in survivors (17). The underlying
causes include microvasculature abnormalities due
to endothelial dysfunction, loss of cardiomyocytes,
and adverse remodeling due to ﬁbrosis. Hence,
developing therapeutics to preserve or regenerate
damaged myocardial tissue might open novel ave-
nues for treating patients with heart diseases.
Accumulating evidence suggests that miR are in-
volved in several pathophysiological processes, and
their dysregulation has been implicated in cardiac
diseases (18–20). Additionally, they are used as
diagnostic or prognostic markers in various diseases
(21). However, studies to determine the effect of
cardiac miR (induced upon injury) on the stem/
progenitor cells that are transplanted for tissueregeneration are limited. Therefore, therapeutic
strategies to augment progenitor cell–based myo-
cardial repair, especially in the context of tissue
ischemia, might be clinically relevant and crucial to
the success of cell-based therapy.
In the present study, we observed that patients
with ischemic heart disease (IHD) have substantial
upregulation of miR-377 in biopsy samples from
myocardial tissue. In contrast, hCD34þ cells exposed
to inﬂammatory stimuli for 12 h show signiﬁcant
decreases in miR-377 expression. Interestingly, miR-
377 mimic treatment diminished proangiogenic
paracrine secretion in hCD34þ cells and reduced
endothelial cell tube formation ability. These data
suggest that the decrease in miR-377 expression
in response to inﬂammatory stimuli might be a
CENTRAL ILLUSTRATION MicroRNA-377 Knockdown Human CD34þ Cells Enhance Cardiac Function
CONTROL EXPERIMENTAL CELL-BASED THERAPY
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Joladarashi, D. et al. J Am Coll Cardiol. 2015; 66(20):2214–26.
LV ¼ left ventricular; STK35 ¼ serine/threonine kinase 35.
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2224compensatory mechanism to protect endothelial cell
function.
Furthermore, reports have shown that miR-377 has
been negatively implicated in various pathological
conditions, such as diabetic nephropathy (22), oxida-
tive stress (23), lung ﬁbrosis, hydrogen peroxide–
induced premature senescence (24), and cancer
(25–28). Our ﬁndings, for the ﬁrst time, demonstrated
that miR-377 critically regulates endothelial cell
function in an inﬂammatory setting. Therefore, we
speculated that strategies to modulate miR-377 to
enhance hCD34þ cell–mediated myocardial repair
might be suitable for therapeutic intervention in the
setting of IHD. We demonstrated this by showing that
transplantation of anti–miR-377–treated hCD34þ cells
enhanced neovascularization, reduced interstitial
ﬁbrosis, and attenuated LV dysfunction. These in vivochanges corroborated well with the in vitro observa-
tions that miR-377 inhibitor treatment enhanced
hCD34þ cell function. A recent study showed that
miR-377 knockdown in mouse mesenchymal stem
cells promoted the angiogenic ability in mouse MI
models (29). Our data demonstrated that anti–miR-377
treatment enhanced the angiogenic potential of
hCD34þ cells, supporting Wen et al. (29), together
demonstrating that miR-377 plays a negative role in
IHD, in line with various other pathophysiological
conditions.
We know that miR bind to target mRNA through
imperfect base pairing and are involved in post-
transcriptional regulation of gene expression by
affecting mRNA stability and translation. On the basis
of computational analysis, we identiﬁed STK35 as a
potential target gene. We observed that miR-377
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The micro-
environment in ischemic tissue detrimentally affects survival
of mobilized/transplanted hCD34þ cells, potentially com-
promising the beneﬁts of cell-based therapies for myo-
cardial ischemia and infarction. Transplantation of miR-377
knockdown hCD34þ cells into ischemic mouse myocardium
promoted cardiac repair and attenuated ventricular
dysfunction.
TRANSLATIONAL OUTLOOK: Further work is needed to
develop clinically applicable strategies to preserve stem cell
function and regenerate damaged myocardial tissue for evalua-
tion in patients with ischemic heart disease.
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2225mimic treatment in hCD34þ cells decreased the levels
of proangiogenic paracrine factors in association with
reduced STK35 expression. miR-377 inhibitor treat-
ment had the opposite effect. More importantly, we
validated that STK35 mRNA is a direct target of miR-
377. These data, together with previous reports, sug-
gest that the negative effects of miR-377 on hCD34þ
cells might be potentially mediated through STK35
signaling.
Enhanced levels of STK35 have been reported in
tissues obtained from patients with colorectal cancer
(30) and shown to be altered in a rodent model of
Parkinson disease (31). Additionally, VEGF stimulates
STK35 expression in endothelial cells (15). A well-
known proangiogenic cytokine, VEGF promotes EPC
migration, differentiation, and angiogenic function.
Our data showed that VEGF treatment in HUVECs
signiﬁcantly decreased miR-377 expression; further-
more, VEGF mRNA expression decreased with
miR-377mimic treatment in HUVECs (Online Figure 5).
Computational analysis revealed that VEGF-A is yet
another potential target of miR-377, as validated in a
previous study onmesenchymal stem cells (29). Taken
together, these data suggest that a negative feedback
loop might exist in regulating miR-377 and VEGF-A
expression. Kinases are of great interest because
they serve as targets in cancer therapeutics. There-
fore, strategies involving pharmacological, genetic, or
miR-basedmanipulation tomodulate STK35-mediated
angiogenesis in cardiomyopathies or cancer might be
clinically relevant.
Beyond STK35, miR-377 has other experimentally
veriﬁed targets relevant to cardiovascular diseases,
such as VEGF-A (29) and hemeoxygenase 1 (23), all
shown to be expressed in endothelial (progenitor)
cells. Wang et al. (22) also demonstrated that miR-377
plays a role in the pathogenesis of diabetic nephrop-
athy through translational repression of target genes
superoxide dismutase 1 and 2 and p21/CDC42/
Rac1-activated kinase 1 (22). Our study showed that
miR-377 negatively regulated hCD34þ cell function in
association with reduced STK35 expression. Taken
together, by regulating the expression of STK35,
VEGF-A, hemeoxygenase 1, and superoxide dismut-
ase 1/2, miR-377 has deleterious effects on endothelial
cell biology and function, possibly through inﬂam-
mation and oxidative stress.
Considering the potential role of miR in a multi-
tude of human diseases (18–20,32–38), targeting
miR-377 represents an exciting prospect for thera-
peutic applications to limit cardiac remodeling and
enhance hCD34þ cell–based tissue repair post-MI,
after stroke, or in other ischemic events or to inhibit
aberrant angiogenesis in cancer.STUDY LIMITATIONS. More studies are required
to determine the role of miR-377 in inﬂammation/
oxidative stress under myocardial ischemic condi-
tions. We showed that miR-377 expression was
increased in various cardiac cell types isolated from
mouse hearts after I-R injury. However, we did not
explore its role in different cell types. Previous studies
have shown the possibility of a pleiotropic role of some
miR in different cell types (39). Therefore, furtherwork
is warranted to clarify the role of miR-377 in progenitor
cell mobilization, cardiomyocyte cell death, and
function during HF, potentially uncovering
therapeutic modalities to modulate the ﬁbrogenesis
process, LV remodeling, and repair of post-ischemic
injury.
CONCLUSIONS
We demonstrated for the ﬁrst time that: 1) miR-377,
which has increased levels in the myocardium of
patients with IHD, negatively inﬂuenced hCD34þ
angiogenic paracrine factors in vitro; and 2) anti–
miR-377 treatment in hCD34þ cells enhanced their
function and attenuated LV dysfunction after intra-
myocardial transplantation in SCID mice with
myocardial I-R injury (Central Illustration). Thus,
knockdown of miR-377 appears to be a feasible
approach to protect against LV remodeling and might
prove to be an attractive therapeutic strategy for cell-
based therapy in patients with HF.
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